The Asian Pacific Association for the Study of the Liver (APASL)



Oncology 2024 Chiba



"Genomics Meets Immunology: Interdisciplinary Approach for Liver Cancer"

Sponsored Seminar 3

Time&Date

9:50~10:50 September 25 (Wednesday) 2024

Venue

Room1 (Fuji AB Sheraton Grande Tokyo Bay Hotel)

1-9 Maihama Urayasu, Japan 279-0031



Real-world clinical impact of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma - a 4-year experience.



Teiji Kuzuya, MD., Ph.D.

National Cancer Center Hospital East, Japan

Professor, Department of Gastroenterology and Hepatology, Fujita Health University, Japan

Co-Sponsored by: The Asian Pacific Association for the Study of the Liver (APASL) Oncology 2024 Chiba / Chugai Pharmaceutical Co., Ltd.